Enasidenib Mesylate

N/A

Report date: 2026/04/18 20:00:19
NMEFirst In Class

Base Information

Drug NameEnasidenib Mesylate
Drug Alias Name依那德尼enasidenibum恩西地平enasidenib伊那尼布 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP], mitochondrial inhibitors
TargetsIsocitrate dehydrogenase [NADP], mitochondrial
Therapy Area/IndicationsSolid tumoursCytopeniaAngioimmunoblastic T-cell Lymphoma +[19] 
Global Approved IndicationsLeukemia, Myeloid, Acute
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2017/08/01
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCelgene CorpAgios Pharmaceuticals IncLaboratoires Servier
China Registration ClassN/A

Develop Information

Active CompaniesHeinrich Heine University DusseldorfBristol Myers Squibb SrlcompanyWashington University School Of Medicine +[8] 
Inactive CompaniesRoswell Park Cancer Institute
Active IndicationsCytopeniaMyelodysplastic SyndromesHepatic Insufficiency +[15] 
Inactive IndicationsSolid tumoursAngioimmunoblastic T-cell LymphomaCholangiocarcinoma +[4] 

Other Information

ATC CodeL01XX59
Related LinksWikipediaDrugBankKEGG